Entering the window period of annual report, the performance of 100 pharmaceutical and biological enterprises increased in advance or slightly

[industry trends of pharmaceutical network] February is the window period of annual report and quarterly report According to data statistics, as of February 7, 2020, 193 pharmaceutical and biological enterprises listed in A-share have disclosed performance forecast Among them, there are 100 pre increased and slightly increased, and 34 pre decreased and slightly decreased Let's take a look at the performance of the pharmaceutical and biological enterprises Profit making enterprises with profits exceeding 50% mainly include Jiuan medical, lanfan medical, Lepu medical, Zhifei biological, Changchun hi tech, hisic, Jinyu medical, etc the profit growth of these enterprises in 2019 has exceeded 50% Among them, Jiuan medical will realize a net profit of 60-80 million yuan attributable to shareholders of Listed Companies in 2019, an increase of 372.93% - 530.58% over the same period of last year Lanfan medical expects that the net profit attributable to shareholders of Listed Companies in 2019 will be 450 million yuan to 550 million yuan, an increase of 30.00% to 60.00% year on year Lepu medical is expected to make a profit of 1.682 billion yuan – 1.852 billion yuan, up 38% - 52% year on year It is estimated that in 2019, Zhifei biology will achieve a net profit of 2.25 billion to 2.54 billion yuan attributable to shareholders of listed companies, an increase of 55% - 75% over the same period of last year Changchun hi tech expects the net profit attributable to the parent company to be RMB 1.61-1.81 billion in 2019, an increase of 60-80% year on year Hisilicon expects that the company's net profit in 2019 will be 500-520 million yuan, and that in 2018 will be 333 million yuan, an increase of 50.05-56.05% year on year Jinyu medical is expected to achieve a net profit of 380-400 million yuan, a year-on-year increase of 62.87% - 71.44%, and a year-on-year net profit of 233 million yuan Among the enterprises listed on the science and technology innovation board in 2019, the performance of Turbo bio is expected to increase 262.43% ~ 287.43% last year, 55.8% for Nanwei micro medicine, 83.24% ~ 94.70% for Bairen medical, 50% ~ 70% for Haier bio, 45% ~ 65% for cardiology, 40% ~ 60% for Borui medical In addition, three pharmaceutical R & D outsourcing service enterprises, i.e tiger pharmaceutical, KANGLONG Huacheng and Zhaoyan new drug, are expected to see a large increase in performance in 2019 Specifically, tiger pharmaceutical expects that in 2019, the net profit attributable to shareholders of listed companies will be 795-902 million yuan, an increase of 68.45% - 91.13% year on year KANGLONG chemical industry is expected to have a net profit of 523 million yuan – 556 million yuan in 2019, up 57% - 67% year on year Zhaoyan new drug is expected to have a net profit of 152-173 million yuan belonging to the shareholders of the listed company from January to December 2019, with a year-on-year change of 40% - 60% The average net profit growth rate of the medical device service industry is 20.23% As the upstream of pharmaceutical R & D, cro's market size has a strong positive correlation with the R & D investment of pharmaceutical companies In recent years, with the promotion of a series of pharmaceutical policies, such as centralized procurement, many pharmaceutical enterprises in China have gradually shifted from generic drugs to innovative drug research and development According to frost Sullivan's research report, the compound growth rate of China's pharmaceutical R & D expenditure from 2014 to 2018 is 16.9% It is expected that the compound annual growth rate will increase to 23.1% from 2018 to 2023, providing a huge development space for cro industry The industry believes that with the development of cro industry, the enterprises with the advantages of the whole industry chain will make pharmaceutical enterprises more sticky to the platform and have a broader development space